Articles
Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and multiple doses

https://doi.org/10.1002/jps.2600770113Get rights and content

Abstract

Ketoprofen (KT; m-benzoylhydratropic acid), a 2-arylpropionic acid (2-APA) nonsteroidal anti-inflammatory drug (NSAID), is marketed and used as a racemic mixture. Although generally the activity of 2-APAs is suggested to be mainly due to the S-enantiomer, information on KT pharmacokinetics is based on measurement of total concentrations of S- and R-enantiomers. In this work, using a crossover fashion, the pharmacokinetics of KT enantiomers following single (50 mg, po) and then multiple (50 mg, q6h for 3 d) doses were delineated in eight healthy subjects. A sensitive stereospecific HPLC assay was used to measure KT enantiomers in plasma and urine, and conjugated KT enantiomers in urine. There were no significant differences between the pharmacokinetic indices calculated after single and multiple administration of KT. In plasma, small but significant differences were found between concentrations of the enantiomers (mean S:R ratios of 0.81 ± 0.19 after single and 0.87 ± 0.11 after repeated doses). Negligible amounts of unchanged KT enantiomers were found in urine. More than 80% of the given doses was found in urine as conjugated S- and R-KT, the predominant enantiomer being S-KT (mean S:R ratios of 1.19 ± 0.05 after single and 1.17 ± 0.05 after repeated doses). No significant difference between the elimination t1/2 of the enantiomers was observed. It is suggested that stereoselective conjugation followed by preferential biliary excretion of the conjugated R-KT enantiomer is responsible for the observed stereoselectivity in the pharmacokinetics of the drug.

References and Notes (17)

  • SinghN.N. et al.

    J. Chromatogr.

    (1986)
  • SinghN.N. et al.

    J. Chromatogr.

    (1986)
  • SinghN.N. et al.

    J. Pharm. Sci.

    (1986)
  • UptonR.A. et al.

    J. Chromatogr.

    (1980)
  • FosterR.T. et al.

    J. Chromatogr.

    (1987)
  • WilliamsK. et al.

    Drugs

    (1985)
  • HuttA.J. et al.

    J. Pharm. Pharmacol.

    (1983)
  • HuttA.J. et al.

    Clin. Pharmacokinet.

    (1984)
There are more references available in the full text version of this article.

Cited by (96)

  • The market of chiral drugs: Chiral switches versus de novo enantiomerically pure compounds

    2018, Journal of Pharmaceutical and Biomedical Analysis
    Citation Excerpt :

    Therefore, the use of the single (S)-ibuprofen was thought that it would give faster onset of action at a lower dosage and would reduce the source of configurational individual variability. After ibuprofen, another “profen” drug (namely, ketoprofen, see Table 1) was submitted to chiral switching and marketed as the (S)-(+)-enantiomer in 1998 [4], and this time the switch has been more straightforward, since the metabolic (R) ⇋ (S) chiral inversion for ketoprofen was shown to be negligible in humans [8]. By merging the data taken from a paper reviewing the chiral switches launched from 1994 to 2002 [4] with those from a more recent review focusing on the period from 2001 to 2011 [9], it emerges that the US Food and Drug Administration (FDA) approved 15 single-enantiomer versions of racemic drugs, i.e., 15 chiral switches have been launched in the period from 1994 to 2011 (see Table 1).

  • Species comparison of enantioselective oral bioavailability and pharmacokinetics of ketoprofen

    2011, Research in Veterinary Science
    Citation Excerpt :

    Inversion is usually unidirectional from R(−) to S(+) KTP except in CD-1 mice where a substantial bi-directional inversion was noted (Jamali et al., 1997). Proof of chiral inversion can only be furnished by the administration of pure enantiomers or if >50% of a racemic dose is recovered from the elimination pathways as one of the enantiomers (Foster et al., 1988). Hence, in this study recourse to literature data is needed.

View all citing articles on Scopus
View full text